The utility of systemic immune inflammatory index in discriminating between gallbladder cancer and xanthogranulomatous cholecystitis: A single-tertiary center experience

Hilmi Anil Dincer,Omer Cennet,Ahmet Bulent Dogrul

DOI: https://doi.org/10.1097/md.0000000000035805

IF: 1.6

2024-02-10

Medicine

Abstract:Xanthogranulomatous cholecystitis (XGC) is a rare variant of chronic cholecystitis and a benign inflammatory disease with nonspecific symptoms and signs. [ 1 ] The gallbladder wall experiences significant proliferative fibrosis due to the inflammatory reaction, which begins with the phagocytosis of bile pigment by macrophages as a result of extravasation of bile to the gallbladder wall that causes the gallbladder wall to thicken asymmetrically. [ 2 ] XGC accounts for 0.7% to 13.2% of all cholecystitis cases. [ 3 ] Gallbladder carcinoma (GBC) is the most prevalent bile tract malignancy, with an incidence of 0.8 to 1.2%. [ 4 ] It is usually diagnosed at a late stage and associated with a poor prognosis, as it progresses with nonspecific symptoms and is diagnosed mostly incidentally in cholecystectomy specimens. [ 5 ] XGC and GBC share similar symptoms and imaging characteristics. [ 6 ] Thus, differentiating between XGC and GBC is not usually easy, as the severe proliferating fibrosis surrounding the gallbladder and adjacent tissues causes more confusion. [ 6 ] The definitive diagnosis depends on the pathological examination of the cholecystectomy material. Distinguishing GBC from XGC in patients with chronic cholecystitis and making an early diagnosis of GBC using preoperative clinical, laboratory, and/or imaging approaches may be helpful for the patients survival and prognosis and choosing the best surgical approach. It is important to have a noninvasive preoperative diagnostic method to distinguish between the 2 diseases.

medicine, general & internal